{"id":31072,"date":"2025-02-17T17:12:00","date_gmt":"2025-02-17T11:42:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31072"},"modified":"2025-02-17T14:12:31","modified_gmt":"2025-02-17T08:42:31","slug":"journavx-for-acute-pain","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain","title":{"rendered":"Vertex\u2019s JOURNAVX: A Historic Milestone in Pain Treatment After a Long Dry Spell"},"content":{"rendered":"\n

A week after Purdue Pharma and the Sackler family agreed to a $7.4 billion<\/strong> settlement over lawsuits related to the opioid painkiller OxyContin<\/strong>, the FDA approved Vertex\u2019s suzetrigine<\/strong>, marking the first novel mechanism for acute pain relief in over 20 years\u2014potentially reshaping the treatment landscape.  <\/p>\n\n\n\n

Marketed as JOURNAVX, suzetrigine is a groundbreaking non-opioid pain reliever designed to manage moderate to severe acute pain in adults. As an oral voltage-gated sodium channel (NaV) inhibitor, it blocks pain signals in the peripheral nervous system before they reach the brain. This approval represents the most significant pain management advancement in over two decades.  <\/p>\n\n\n\n

JOURNAVX is intended for adults experiencing moderate to severe acute pain<\/a>, typically caused by surgery or injury. While opioids and other painkillers are commonly used for such conditions, their potential for addiction has been a major concern.<\/p>\n\n\n\n

Each year, over 80 million<\/strong> people in the U.S. are prescribed medication for moderate to severe acute pain, with about half receiving opioids. Among them, approximately 85,000<\/strong> develop opioid use disorder. As per DelveInsight\u2019s estimates, postoperative and trauma pain were found to contribute the most cases in the total diagnosed acute pain cases<\/a> in the United States with approximately 80%<\/strong> of cases put together.<\/p>\n\n\n\n

In the United States, severity-specific acute pain cases were mostly mild and moderate, with severe cases accounting for only ~15%<\/strong> of the diagnosed acute pain incident cases in 2023.<\/p>\n\n\n\n

Unlike opioids, JOURNAVX works by blocking pain signals in the peripheral nervous system rather than the brain, reducing its potential for addiction. In clinical trials, its side effects have generally been mild, including itching, rash, muscle spasms, and elevated levels of creatine phosphokinase in the blood.<\/p>\n\n\n\n

The approval marks the culmination of a lengthy and meticulous development journey, with Vertex achieving success where several other companies had abandoned efforts to develop a treatment using a similar mechanism of action.  <\/p>\n\n\n\n

The industry\u2019s pursuit of a breakthrough drug began over two decades ago when researchers in Asia identified two genetic mutations that provided deeper insights into how pain signals travel through the body. These discoveries highlighted the NaV1.7 channel as a crucial transmitter of pain signals. Blocking pain-signaling ions from passing through this channel would prevent them from reaching the brain. However, the target proved difficult to pin down due to the high similarity among NaV channels, making it challenging to selectively inhibit NaV1.7.  <\/p>\n\n\n\n

\"JOURNAVX-Development-Timeline\"<\/figure>\n\n\n\n

While many companies relied on patch-clamp electrophysiology\u2014a method for measuring ion channel currents developed in the 1970s\u2014Vertex took a more advanced approach. The company utilized an electrical stimulation voltage ion probe reader, enabling it to screen a larger number of potential compounds with greater efficiency.  <\/p>\n\n\n\n

Another key differentiator for Vertex was its decision to explore the Nav1.8 channel, which plays a closely related role to Nav1.7. Despite setbacks in three clinical trials, the first of which began a decade ago, Vertex remained persistent. Its Nav1.8 inhibitors failed to show success, but two years ago, the company finally made a breakthrough with JOURNAVX, which was then advanced to late-stage trials.  <\/p>\n\n\n\n

In two Phase III studies, JOURNAVX demonstrated significantly better pain relief than a placebo in the first 48 hours following tummy tuck and bunion removal procedures. However, the trials did not meet their secondary endpoints, as JOURNAVX proved no more effective than the commonly used opioid painkiller Vicodin<\/strong>.<\/p>\n\n\n\n

Vertex is positioning JOURNAVX for potential approval in chronic pain<\/a>, which could significantly expand its patient base. However, clinical performance in this area has been inconsistent. In December, the company released phase II trial results for lumbosacral radiculopathy. Although the study met its primary endpoint, the news caused a decline in Vertex\u2019s stock price.  <\/p>\n\n\n\n

While safety is the primary factor that sets JOURNAVX apart from the opioids it will compete against, pricing is another key distinction. Vertex plans to charge $15.50<\/strong> for a 50-mg dose of JOURNAVX, totaling $420 <\/strong>for a two-week treatment course. Additionally, Vertex is studying suzetrigine for peripheral neuropathic pain (PNP). A Phase III pivotal trial for suzetrigine in patients with painful diabetic peripheral neuropathy is underway.<\/p>\n\n\n\n

The approval of JOURNAVX has driven momentum in the non-opioid pain market, which includes companies such as Tris Pharma, Latigo Biotherapeutics, Algiax Pharmaceuticals, Collegium Pharmaceuticals, Protega Pharmaceuticals, Cara Therapeutics, and SiteOne Therapeutics<\/strong>, among others. <\/p>\n\n\n\n

Just days after regulators approved Vertex Pharmaceuticals\u2019 JOURNAVX, Germany\u2019s Algiax Pharmaceuticals<\/strong> released Phase IIa data for a potential rival. On February 4, 2025, the company announced that its lead candidate, AP-325<\/strong>\u2014a non-opioid pain drug\u2014demonstrated a rapid onset of action and sustained pain relief in patients with chronic neuropathic pain<\/a>.<\/p>\n\n\n\n

AP-325 is a small molecule that modulates GABAA receptors, aiming to restore balance between excitatory and inhibitory neuronal signals. By consistently preventing excessive neuronal activation, it holds promise for transforming neuropathic pain treatment.<\/p>\n\n\n\n

Algiax\u2019s randomized Phase IIa trial involved 99 patients, assessing AP-325 as a monotherapy for peripheral post-surgical neuropathic pain. The drug showed a \u201cclinically meaningful\u201d reduction in pain within two weeks of treatment. Over 25% of patients treated with AP-325 experienced a pain reduction of \u226550%, compared to just 11% in the placebo group. <\/p>\n\n\n\n

Furthermore, more than half of those receiving AP-325 did not require rescue medication, compared to 21% in the placebo group. Algiax noted that the drug\u2019s efficacy, as measured by the \u201cnumber needed to treat,\u201d aligns with opioid-based treatments, but without the associated safety risks. Safety data for AP-325 indicated side effects similar to those of the placebo, with no central nervous system effects such as sedation, drowsiness, or dizziness.<\/p>\n\n\n\n

On the same day, SiteOne Therapeutics<\/strong> reported that interim results from the Phase I trial of STC-004<\/strong> indicate the lead NaV1.8 inhibitor is well-tolerated and has a half-life suitable for once-daily oral administration. Furthermore, pharmacodynamic assessments confirm that the candidate is effectively interacting with its target. The company, which secured $100 million<\/strong> in a Series C round last December, intends to advance STC-004 into Phase II trials in the second half of the year.<\/p>\n\n\n\n

In January 2025, Tris <\/strong>announced positive Phase III results for its non-opioid pain medication, cebranopadol<\/strong>, demonstrating strong efficacy and a favorable safety profile in patients recovering from abdominoplasty. Meanwhile, Latigo <\/strong>launched in February 2024, securing $135 million<\/strong> in a Series A funding round for its NaV1.8 inhibitor, LTG-001<\/strong>.  <\/p>\n\n\n\n

Additionally, Collegium Pharmaceuticals<\/strong> utilizes its proprietary DETERx platform to enable extended-release drug delivery while preventing abuse and tampering. Cara Therapeutics<\/strong> is developing novel chemical compounds that target peripheral kappa opioid receptors<\/a> to treat pruritus. Meanwhile, Protega Pharmaceuticals<\/strong> recently received approval for an opioid formulation designed to deter abuse.<\/p>\n\n\n\n

The evolving dynamics of pain management are certainly intriguing, especially with multiple players working on developing new treatments. This suggests a promising future for pain management options.<\/p>\n\n\n\n

\"Acute<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

A week after Purdue Pharma and the Sackler family agreed to a $7.4 billion settlement over lawsuits related to the opioid painkiller OxyContin, the FDA approved Vertex\u2019s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years\u2014potentially reshaping the treatment landscape.   Marketed as JOURNAVX, suzetrigine is a groundbreaking non-opioid pain reliever […]<\/p>\n","protected":false},"author":14,"featured_media":31074,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[21364,16908,22451,22453,19672,22452],"industry":[17225],"therapeutic_areas":[17241],"class_list":["post-31072","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-acute-pain","tag-chronic-pain","tag-journavx","tag-moderate-to-severe-acute-pain","tag-neuropathic-pain","tag-suzetrigine","industry-pharmaceutical","therapeutic_areas-musculoskeletal"],"acf":[],"yoast_head":"\nVertex\u2019s JOURNAVX Sets a New Standard for Pain Management<\/title>\n<meta name=\"description\" content=\"FDA has approved Vertex\u2019s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vertex\u2019s JOURNAVX Sets a New Standard for Pain Management\" \/>\n<meta property=\"og:description\" content=\"FDA has approved Vertex\u2019s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-17T11:42:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/17140720\/journavx-for-acute-pain.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vertex\u2019s JOURNAVX Sets a New Standard for Pain Management","description":"FDA has approved Vertex\u2019s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain","og_locale":"en_US","og_type":"article","og_title":"Vertex\u2019s JOURNAVX Sets a New Standard for Pain Management","og_description":"FDA has approved Vertex\u2019s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years.","og_url":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-17T11:42:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/17140720\/journavx-for-acute-pain.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain","url":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain","name":"Vertex\u2019s JOURNAVX Sets a New Standard for Pain Management","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/17140720\/journavx-for-acute-pain.png","datePublished":"2025-02-17T11:42:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"FDA has approved Vertex\u2019s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/journavx-for-acute-pain#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/17140720\/journavx-for-acute-pain.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/17140720\/journavx-for-acute-pain.png","width":466,"height":284,"caption":"journavx-for-acute-pain"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/17140720\/journavx-for-acute-pain-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Acute Pain<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic pain<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">JOURNAVX<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">moderate to severe acute pain<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">neuropathic pain<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">suzetrigine<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Pain<\/span>","<span class=\"advgb-post-tax-term\">Chronic pain<\/span>","<span class=\"advgb-post-tax-term\">JOURNAVX<\/span>","<span class=\"advgb-post-tax-term\">moderate to severe acute pain<\/span>","<span class=\"advgb-post-tax-term\">neuropathic pain<\/span>","<span class=\"advgb-post-tax-term\">suzetrigine<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 17, 2025","modified":"Updated on Feb 17, 2025"},"absolute_dates_time":{"created":"Posted on Feb 17, 2025 5:12 pm","modified":"Updated on Feb 17, 2025 2:12 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31072"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31072\/revisions"}],"predecessor-version":[{"id":31080,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31072\/revisions\/31080"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31074"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31072"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31072"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}